Overview

Precision Biopsy, LLC was formed in partnership with Allied Minds to develop and commercialize novel technology for the accurate diagnosis of prostate cancer. The company’s diagnostic technology uses advanced spectroscopy imaging techniques in combination with tissue biopsy. For the first time, this unique ability will eliminate random prostate biopsies that are subject to sampling errors and can lead to inaccurate grading and staging of the disease.

The scientific founders, professors Priya Werahara and John Daily of the University of Colorado, have long studied the morphology of cancer tissue. Combining their knowledge of advanced spectroscopy techniques has resulted in the ability to image the precise location of cancer in the prostate.

Announcements

See All
24-Apr-2012

Fast Company Magazine: How A Colorado Town's Med-Tech Startups Thrive On Shoestring Budgets

(http://www.fastcompany.com/1835136/montview-boulevard) by Garth Sundem In most cities, academic researchers have to drive across town, or even through othe..

06-Jul-2011

Precision Biopsy Secures New Funding Led by Allied Minds, Inc.

Boston, MA – Precision Biopsy formally closes a $2.5MM round of funding to kickoff the commercialization phase of a novel prostate cancer detection technology developed ..

Please visit Precision Biopsy at

Contact Precision Biopsy

  • • Required
  • Captcha Image
  • Phone Email